Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Injection of 68Ga-NI-FAPI.
- Who it may be relevant to
- Registry conditions: Tumor, Cardiovascular Diseases, Pulmonary Fibrosis, Rheumatic Immune Diseases Involving Large Blood Vessels. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
Interventions
- Drug Injection of 68Ga-NI-FAPI
Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight
Primary outcome measures
- Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04 [Time frame: Within 30-120 minutes after intravenous injection of imaging agent]
Eligibility criteria
Inclusion criteria
- 1: 18-85 years old
2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis
3: Ability to understand and sign informed consent forms
4: Expected survival period exceeding 6 months and able to receive follow-up
5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc
Exclusion criteria
- 1: Pregnant or lactating women
2: Patients allergic to research drug ingredients
3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L)
4: Patients who participate in other clinical trials and interfere with the results of this study
5: Patients with severe illness who cannot cooperate with the examination
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union — Beijing
Identifiers
NCT: NCT07464132 · I-25PJ0568